WO2009049813A3 - Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption - Google Patents

Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption Download PDF

Info

Publication number
WO2009049813A3
WO2009049813A3 PCT/EP2008/008515 EP2008008515W WO2009049813A3 WO 2009049813 A3 WO2009049813 A3 WO 2009049813A3 EP 2008008515 W EP2008008515 W EP 2008008515W WO 2009049813 A3 WO2009049813 A3 WO 2009049813A3
Authority
WO
WIPO (PCT)
Prior art keywords
risk
vein thrombosis
deep vein
united
producing
Prior art date
Application number
PCT/EP2008/008515
Other languages
English (en)
French (fr)
Other versions
WO2009049813A2 (de
Inventor
Katrin Mittmann
Original Assignee
Bayer Schering Pharma Ag
Katrin Mittmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Katrin Mittmann filed Critical Bayer Schering Pharma Ag
Priority to EP08802837A priority Critical patent/EP2209475A2/de
Publication of WO2009049813A2 publication Critical patent/WO2009049813A2/de
Publication of WO2009049813A3 publication Critical patent/WO2009049813A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Einphasische orale Kontrazeptiva, enthaltend eine Kombination von 2.0 mg Dienogest und 0.030 mg Ethinylestradiol oder 2.0 mg Dienogest und 0.020 mg Ethinylestradiol zu nx21 täglichen Dosiseinheiten mit nachfolgend nach nx21 maximal 7 täglichen einnahmefreien oder placebohaltige Dosiseinheiten verwendet, wobei n gleich 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, und 17 ist, realisieren eine Begrenzung/Verminderung des Risikos einer Tiefen-Venen-Thrombose in Einheit mit einer oralen Kontrazeption. Es wird ein geeignetes kontrazeptives Mittel mit verlängerter Einnahmezeit der hormonhaltigen Tagesdosiseinheiten bereit gestellt, welches trotz der verlängerten Einnahmezeit das Risiko einer Tiefen-Venen-Thrombose auf dem gleichen Niveau wie beim entsprechenden konventionellen oralen Kontrazeptivum hält und damit im vertretbaren Rahmen gestaltet.
PCT/EP2008/008515 2007-10-11 2008-10-09 Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption WO2009049813A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08802837A EP2209475A2 (de) 2007-10-11 2008-10-09 Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97921007P 2007-10-11 2007-10-11
US60/979,210 2007-10-11

Publications (2)

Publication Number Publication Date
WO2009049813A2 WO2009049813A2 (de) 2009-04-23
WO2009049813A3 true WO2009049813A3 (de) 2009-06-25

Family

ID=40435736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008515 WO2009049813A2 (de) 2007-10-11 2008-10-09 Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption

Country Status (4)

Country Link
US (2) US20090099144A1 (de)
EP (1) EP2209475A2 (de)
DE (1) DE102008051140B4 (de)
WO (1) WO2009049813A2 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655031A1 (de) * 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
WO2006087173A1 (de) * 2005-02-15 2006-08-24 Bayer Schering Pharma Aktiengesellschaft Pharmazeutisches präparat zur kontrazeption
WO2007042110A1 (de) * 2005-10-13 2007-04-19 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung eines einphasigen pharmazeutischen präparates zur oralen therapie der dysfunktionellen uterinen blutung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655031A1 (de) * 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
WO2006087173A1 (de) * 2005-02-15 2006-08-24 Bayer Schering Pharma Aktiengesellschaft Pharmazeutisches präparat zur kontrazeption
WO2007042110A1 (de) * 2005-10-13 2007-04-19 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung eines einphasigen pharmazeutischen präparates zur oralen therapie der dysfunktionellen uterinen blutung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WIEGRATZ I ET AL: "Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters", CONTRACEPTION, GERON-X, INC., LOS ALTOS, CA, US, vol. 78, no. 5, 1 November 2008 (2008-11-01), pages 384 - 391, XP025506905, ISSN: 0010-7824, [retrieved on 20080902] *

Also Published As

Publication number Publication date
EP2209475A2 (de) 2010-07-28
US20090099144A1 (en) 2009-04-16
WO2009049813A2 (de) 2009-04-23
DE102008051140B4 (de) 2010-06-10
DE102008051140A1 (de) 2009-04-16
US20090099145A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2006042021A3 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
WO2005007112A3 (en) Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
BG66095B1 (bg) Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
NZ589445A (en) Rasagiline for parkinson's disease modification
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2009048594A3 (en) Multicomponent bioactive intravaginal ring
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP0966966A3 (de) Nefazodon enthaltende Dosierungsform
WO2004098517A3 (en) Methods of hormonal treatment utilizing extended cycle contraceptive regimens
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
MX2009010320A (es) Regimen anticonceptivo oral.
WO2006138317A3 (en) Dosage regimen for prasugrel
NZ598702A (en) A micro-rna family that modulates fibrosis and uses thereof
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2007145863A3 (en) Sustained release formulation of naltrexone
AU2003290015A1 (en) Mastitis treatment
WO2009049813A3 (de) Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption
TW200731977A (en) Use of estradiol valerate in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008802837

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802837

Country of ref document: EP

Kind code of ref document: A2